$PIQ (I don't rate trendlines but this is a beauty)ASX:PIQ Weakly lifting on volume and resting on the trendline. one more pull back to screw the punters and then she blows. IMO etc etc.
PIQ trade ideas
$PIQ cr at 77 this week. Right on support.Lots of newsflow on this thing coming. Ive drawn a speculative red curve. These raises inevitably test the raise price and double whammy with director Dick selling shares.
Having said that I reckon they'll have great newsflow this year and Europe agreements should be the highest priority along with production and commercialisation.
$1.12 the break imo on the W.
Cheers
$PIQ nice run here. BUllflag. DIMI!!!Bullflag.
I expect. deep pullback once she hits the top rail so I'll let go before then. I'll watch for a re-entry after that.
$PIQ news reentry into wedge.very good risk reward play here in my opionion. Bought the change in momo back up into that wedge. Sell some at the top of the range and hopefully another catalyst breaks it out to the topside. time will tell.
$PIQ - Proteomics International continuing its rapid climb$PIQ - Proteomics International continuing its rapid climb
Good little stock with lots of momentum. All my indicators are headed in the right direction - probably a bit expensive at the moment based on the RSI - but with diabetes being the next big global disease especially in the western world Ill take a punt and hold for the medium to long term unless a sudden significant reversal.
Todays announement was: "Proteomics signs collaboration agreement with US big pharma to accelerate diabetic kidney disease & heart disease drug discovery using PromarkerD"
Proteomics International Laboratories Limited is a biological research and drug discovery company. The Company operates in three business units unified by a technology platform: Analytical services, which includes specialist contract research, analytical testing and consultancy; Diagnostics, which includes biomarkers of disease and personalized medicine, and Therapeutics, which includes peptide drug discovery from venoms. The Company focuses on the PromarkerD, a proteomics-derived predictive and diagnostic test for diabetic kidney disease. The Company focuses on its diagnostics portfolio using the Promarker platform, and is investigating proteins associated with endometriosis, mesothelioma and other conditions. The Company has a therapeutic drug discovery program targeting new analgesic (painkilling) and antibiotic drug compounds. The Company also has a laboratory to analyze the make-up of biosimilar drugs as being like-for-like with the brand name drugs they seek to replace.
memory of the last peakEnter a dragon den with this little stock , as always with Biotech , hard to tell which way it will end up , just like bitcoin.
